Article Text

Download PDFPDF

A randomised, placebo controlled trial of low level laser therapy for activated Achilles tendinitis with microdialysis measurement of peritendinous prostaglandin E2 concentrations
  1. J M Bjordal1,
  2. R A B Lopes-Martins2,
  3. V V Iversen1
  1. 1Physiotherapy Science, University of Bergen, Bergen, Norway
  2. 2University of São Paulo, São Paulo, Brazil
  1. Correspondence to:
 Dr Bjordal
 Physiotherapy Science, University of Bergen, Bergen, Norway; jmbjor{at}
  1. R Chow3
  1. 3Castle Hill Medical Centre, Castle Hill, NSW, Australia; rtchow{at}


    Background: Low level laser therapy (LLLT) has gained increasing popularity in the management of tendinopathy and arthritis. Results from in vitro and in vivo studies have suggested that inflammatory modulation is one of several possible biological mechanisms of LLLT action.

    Objective: To investigate in situ if LLLT has an anti-inflammatory effect on activated tendinitis of the human Achilles tendon.

    Subjects: Seven patients with bilateral Achilles tendinitis (14 tendons) who had aggravated symptoms produced by pain inducing activity immediately before the study.

    Method: Infrared (904 nm wavelength) LLLT (5.4 J per point, power density 20 mW/cm2) and placebo LLLT (0 J) were administered to both Achilles tendons in random blinded order.

    Results: Ultrasonography Doppler measurements at baseline showed minor inflammation through increased intratendinous blood flow in all 14 tendons and measurable resistive index in eight tendons of 0.91 (95% confidence interval 0.87 to 0.95). Prostaglandin E2 concentrations were significantly reduced 75, 90, and 105 minutes after active LLLT compared with concentrations before treatment (p  =  0.026) and after placebo LLLT (p  =  0.009). Pressure pain threshold had increased significantly (p  =  0.012) after active LLLT compared with placebo LLLT: the mean difference in the change between the groups was 0.40 kg/cm2 (95% confidence interval 0.10 to 0.70).

    Conclusion: LLLT at a dose of 5.4 J per point can reduce inflammation and pain in activated Achilles tendinitis. LLLT may therefore have potential in the management of diseases with an inflammatory component.

    • LLLT, low level laser therapy
    • NSAID, non-steroidal anti-inflammatory drug
    • PGE2, prostaglandin E2
    • RI, resistive index
    • low level laser therapy
    • tendinitis
    • Achilles
    • inflammation
    • microdialysis

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Osteoarthritis, tendinitis, and painful spinal disorders are the most common musculoskeletal disorders in modern society.1–4 A whole range of different treatments such as locally applied or orally administered drugs, electrotherapies, joint mobilisation techniques, exercise therapy, cognitive behavioural therapies, and alternative treatments are currently in use for these conditions.5–9 Non-steroidal anti-inflammatory drugs (NSAIDs) and steroid injections have been the most prevalent form of treatment for short term pain relief.10–12 Most treatments exhibit some pain relieving effect against osteoarthritis and tendinopathy.13,14 However, it is unclear whether any electrophysical agents have anti-inflammatory effects. A review on the biological effects of ultrasound therapy suggests that there is no evidence that it has any major anti-inflammatory effect.15 For low level laser therapy (LLLT) two important biological responses have been targeted as possible mechanisms for its beneficial clinical effects in clinical trials on tendinopathy and osteoarthritis.16,17 The first possible biological response is a modulating, dose dependent effect on fibroblast metabolism and collagen deposition. This response has been observed in a broad range of controlled studies on cell cultures and animals.18–22 The second possible mechanism is similar to that of NSAIDs and steroids. Controlled laboratory trials have revealed that LLLT can reduce inflammation through reduction of PGE2 concentrations and inhibition of cyclo-oxygenase 2 in cell cultures.23,24 This effect has also been shown in an animal trial, but to our knowledge no study has yet confirmed such an anti-inflammatory effect in humans.25 Microdialysis is a technique used to assess peritendinous inflammation in normal and symptomatic tendons.26,27 Although some researchers have questioned the presence of inflammation in chronic tendinopathies, others have shown that structural tendon damage and ruptures correlate significantly with the degree of inflammation.28–30 In addition, loading of tendon cells increased the expression of cyclo-oxygenase 2 and the release of prostaglandin E2 (PGE2) in vitro and peritendinous PGE2 concentrations in a human experimental model of healthy Achilles tendons.31 In healthy subjects, this activity induced release of PGE2 could be blocked by a cyclo-oxygenase 2 inhibitor (celecoxib).27 Therefore microdialysis after activity induced inflammation seems to be a suitable method for assessing the anti-inflammatory effect of LLLT in humans.


    Patient sample

    Patients were recruited through primary care doctors and physiotherapists. Patients who sought help for their bilateral Achilles pain were targeted, and given the opportunity to participate before standard treatment was started. Inclusion criteria were: signed written informed consent statement; age 20–60 years; bilateral symptoms of pain and tenderness from the Achilles tendons that could be aggravated by some type of physical activity; willingness to perform the type of physical activity that by experience aggravated Achilles tendon pain; pathological sonographic appearance of tendon thickening and structural alterations of tendon matrix. Exclusion criteria were: systemic inflammatory disease; previous operations on Achilles tendons; pregnancy; mental inability to understand the consequences of participation; NSAID treatment during the preceding four weeks; steroidal treatment during the preceding six months; monogenic familial hypercholesterolaemia (may cause Achilles tendon xanthomas).

    Examination procedure and outcome measures

    Each patient was examined by interview about symptom characteristics, symptom duration, and specific activities that caused aggravation of Achilles tendon symptoms. A physical examination was then performed. After location of the most painful spot identified by finger palpation, pressure pain threshold was measured as the average of three tests with pressure pain algometry. This test was performed by pressing a circular metallic tip of area 1 cm2 with gradually increasing force to the most painful spot of the tendon. The patient was told to respond by saying “stop” when the feeling of pressure changed to pain. Before the experiment, this test was checked on healthy subjects for test-retest reliability; the intraclass correlation coefficient was 0.79 and standard deviation 0.39 kg/cm2, which is similar to other reliability studies for pressure pain threshold.32–34

    Functional ability was tested by measuring the mean distance of three repetitions reached in the single leg hop test.35 Ultrasonography (Siemens Sonoline G60) was performed to ensure the exact location of tendon pathology. Tendon thickness was measured using calibrated callipers, and structural alteration of the tendon matrix was described. Tendon vascularisation was examined by power Doppler. If possible, peritendinous or intratendinous arterial blood flow velocity was also measured, as they can be used to detect signs of inflammation through the arterial resistive index (RI), which is a measure of vasodilatation and inflammation.36 RI is defined as: (systolic peak velocity minus end diastolic velocity)/systolic peak velocity. Values of less than 1 (normal) indicate inflammation.

    Microdialysis was performed by first giving a local anaesthetic injection (xylocaine, 20 mg/ml; AstraZeneca, Oslo, Norway) at the insertion site 30 mm cranially to the centre of pathology. After four to five minutes, the microdialysis membrane (CMA/60, cut off 20 kDa, membrane length 30 mm, outer diameter 0.6 mm; CMA, Stockholm, Sweden) was inserted into the peritendinous tissue parallel to the Achilles tendon. Insertion into the tissue is achieved with the help of a slit cannula introducer which leaves the catheter in place when withdrawn. Before withdrawal of the introducer, the position of the membrane was checked by ultrasonography. The microdialysis membrane and tubes were then coupled to a syringe containing isotonic 0.9% salt water. Syringes for both Achilles tendons were then placed in a syringe pump (CMA/100) and adjusted to give 2 μl/min. Samples of the harvested fluid were collected every 15 minutes. After a stabilisation period of 60 minutes, baseline levels were registered for another 60 minutes before laser treatment was administered. PGE2 concentrations after treatment were recorded for 105 minutes. PGE2 concentration in the dialysate was analysed by a high sensitivity Prostaglandin E2 Enzyme Immunoassay Kit (Electra-box Diagnostica AS, Stockholm, Sweden). The washing, the adding of substrate solutions and stop solutions, and the analyses were performed according to the manufacturers’ specifications. For each well, the absorbance was read using a microplate reader (Spectramax; Molecular Devices, Sunnyvale, California, USA) set to 450 nm, with wavelength control.


    LLLT was administered by a GaAs laser with an infrared wavelength of 904 nm (Irradia AB, Stockholm, Sweden) with a laser probe consisting of three laser diodes placed longitudinally 9 mm apart. On the laser probe, an A/B switch determined whether active or sham irradiation was given. During operation the laser appeared identical for both active and sham irradiation, because of the invisible nature of the infrared laser beam and the same blinking red diode and descending time counter. The output of the laser averaged 10 mW for each diode, which was tested and calibrated before and after treatment for every patient by technical staff not otherwise involved in the experiment. The peak power for each laser pulse was 10 W and pulse duration was 200 nanoseconds (10−9 seconds), delivered by a frequency of 5000 Hz. The spot area was 0.5 cm2 giving a power density (fluence) of 20 mW/cm2. Each patient was treated for 180 seconds, and the dose of active treatment was 1.8 J for each of three points along the Achilles tendons, giving a total of 5.4 J per tendon.

    Blinding and randomisation procedure

    The trial was designed to achieve randomised concealed allocation to groups and double blinding. As patients were acting as their own controls, both Achilles tendons were treated, but only one received active treatment. Which side should be treated with the laser probe in switch position A or B was decided for each patient by drawing one of 10 opaque envelopes containing a written character A or B (five of each). The A/B switch on the laser was then switched to the character drawn, and treatment started for the right leg first. Thus the allocation of tendon to groups was concealed from patients, therapist, and observer. The code of the A/B switch positions on the laser probe was only known to the technical staff who calibrated the laser before and after each patient. The code was not broken until all treatments and analyses were finished.

    Ethical approval

    The experiments in this study were performed with the approval of, and in accordance with the regulations laid down by, the regional ethics committee of Western Norway (no 144/03). Participants gave signed informed consent.


    Randomisation procedure

    Four right side and three left side Achilles tendons were given active treatment.

    Pressure pain threshold

    There was a small, but non-significant mean decrease (−0.05 kg/cm2) in the pressure pain threshold from the start of the observation period to immediately before treatment. However, after treatment it had increased by 0.19 kg/cm2 (95% confidence interval (CI) 0.04 to 0.34) in the laser group, whereas a decrease of −0.21 kg/cm2 (95% CI +0.04 to −0.46) was recorded for the placebo group from the start to the end the observation period. The mean difference in change was 0.40 kg/cm2 (95% CI 0.10 to 0.70) (fig 1).

    Figure 1

     Mean pressure pain thresholds of three recordings from each tendon with their respective 95% confidence intervals grouped by treatment allocation.

    Inflammatory marker PGE2 concentrations

    In the laser group, a small decrease in PGE2 concentration was seen first one hour after treatment, and then gradually decreasing from baseline (1.0) to 0.72 (95% CI 0.58 to 0.86) at the last time point 105 minutes after treatment. For the placebo group, PGE2 concentrations increased gradually in the period after treatment from baseline to 1.30 (95% CI 1.48 to 1.12) at the last observation. For the laser group, there was a significant difference in both the pre-treatment and post-treatment means (p  =  0.0269) and the difference in change between the groups (p  =  0.0096) (fig 2).

    Figure 2

     Laser effect on inflammation as measured by prostaglandin E2 (PGE2) concentrations in peritendinous tissue. Mean post-treatment PGE2 concentrations and their respective 95% confidence intervals relative to the mean pre-treatment baseline results are shown. Values were recorded at seven consecutive 15 minute intervals (total 165 minutes after treatment), and the significant between-groups difference at the last time point is indicated by an asterisk.

    Single jump hop test

    Because of the fragile microdialysis membrane and the importance of harvesting fluid meticulously, the single hop test could only be performed before and after microdialysis. Both groups showed a decrease in the single jump hop test after treatment. However, the mean decrease was significantly less (p  =  0.025) for the laser treated group (10.6 cm (95% CI 3.5 to 17.7) than for the placebo group (18.4 cm (95% CI 12.3 to 24.5)).

    Ultrasound Doppler scanning

    At baseline all 14 tendons exhibited increased peritendinous and intratendinous blood flow when assessed by colour Doppler in a relaxed position of ankle plantar flexion. At follow up, blood flow measured by colour Doppler seemed to have decreased in all tendons, but no arbitrary assessment was performed. The decreased flow was thought to be a result of the necessary physical inactivity in the experimental set up.

    For power Doppler measurements of blood flow, velocity and RI could only be measured at baseline in eight tendons, five in the active LLLT group and three in the placebo LLLT group. The mean RI for these eight tendons indicated a small inflammatory reaction, with RI 0.91 (95% CI 0.87 to 0.95) (fig 3). No significant differences between groups were observed after treatment for any ultrasound measures.

    Figure 3

     Colour Doppler image of a transverse section of Achilles tendon showing intratendinous blood vessels (right hand frame) and power Doppler (left hand frame) assessment of intratendinous blood flow velocity in systolic peak (26.1 cm/s) and diastolic end (2.8 cm/s), giving a resistive index of 0.89, indicating minor inflammation.

    Side effects and adverse reactions

    The experiment was well tolerated by all patients. Local injection of analgesic (xylocaine) and placement of the microdialysis catheter caused minor transient pain at the time of insertion. Likewise, the application of the pressure pain algometer caused increased tenderness in the area of the Achilles tendon, probably partly because of the repeated pain threshold pressure applications and partly because the effect of the local anaesthetic was tailing off. None of the patients experienced infections or other complications, and they all reported that being bored was a greater problem than the transient pain they experienced.


    To our knowledge, other physiotherapy methods have failed to produce relevant anti-inflammatory effects in the laboratory. In this trial, we show that LLLT can suppress inflammation, as measured by a reduction in the inflammatory marker PGE2. In addition, clinical indices of small, but significant improvements in pressure pain and single hop function were observed. The ultrasound measurements were not suitable for detecting differences at follow up mainly because the experimental set up, with hours of physical inactivity, reduces peripheral circulation to a minimum and impairs ultrasound measurements. Still, our baseline ultrasound results may be important for confirming both that pain was actually related to Achilles pathology and a small degree of inflammation was possibly present.37 We devised the protocol with prior pain inducing activity, and the ultrasound measurements of RI seem to suggest that a small inflammatory reaction had been induced. Our findings possibly contradict other claims that inflammation is not present in Achilles tendinopathy.28 In our opinion, this is not a true contradiction, but rather an elaboration in the sense that inflammation may play a small, but important part in episodes of symptom aggravation. This question remains to be more thoroughly investigated.

    The small increase in PGE2 concentration seen in both active and placebo groups immediately after treatment was probably caused by a local reaction to the pressure pain threshold testing at this point. Still the results indicate that the anti-inflammatory modulation is present within one hour of application. Our data provide a basis for further exploration and optimisation of LLLT in clinical settings. For tendinopathies, several treatment options exist, but none has been reported to be irrevocably more effective than the others. There are several weaknesses of our study. We only used one fixed LLLT dose and a short follow up of one hour, and therefore the range limits for optimal dose and the duration of the effect remain to be determined. Because of the short duration of the experiment, it would also be inappropriate to conclude that LLLT is effective for Achilles tendinopathy. More laboratory trials are needed to determine optimal dose ranges and intervals between applications, and finally these results must be confirmed in larger clinical trials of longer duration. Because of the diversity of subacute and chronic Achilles tendinopathy, LLLT cannot be recommended as a monotherapy, but should rather be seen as an adjunct to exercises and stretching in an optimal treatment package.38

    What is already known on this topic

    • Low level laser therapy has produced heterogeneous results in clinical trials investigating musculoskeletal pain

    • The mechanism underlying the positive results is not known

    What this study adds

    • Low level laser therapy can reduce pain by modulating inflammation

    What may be more important is that our findings provide an explanation of the biological mechanism behind the positive clinical LLLT results reported for osteoarthritis and rheumatoid arthritis.39,40 LLLT is considered by some as one of the most promising non-pharmacological interventions for inflammatory arthritis.41 In view of the serious concerns recently raised about side effects of both traditional NSAIDs and cyclo-oxygenase 2 inhibitors in arthritis management, LLLT is a well tolerated alternative that may become a useful treatment for large groups of patients.42


    In conclusion, these results indicate that LLLT can be used to reduce inflammatory musculoskeletal pain. Because of its rapid action and few side effects, more research is needed to optimise treatment protocols particularly for inflammatory arthritis.


    This work was supported by a grant from The Norwegian Research Council.



    This study is of importance in that it provides direct evidence, for the first time in human volunteers, that low level laser therapy (LLLT) with 904 nm laser reduces the production of PGE2 after local, transcutaneous application for Achilles tendinitis. It adds significantly to other studies that have shown a reduction in PGE2 in animal models and cell cultures. Several mechanisms have been proposed to explain how pain is modulated by LLLT. This study provides additional support for an anti-inflammatory effect. Given the serious concerns with long term intake of NSAIDs, the potential for application of LLLT for Achilles tendinitis and inflammatory conditions, such as rheumatoid arthritis, is also raised. Interestingly, this study suggests an inflammatory component to Achilles tendinitis not previously recognised. LLLT for the management of Achilles tendinitis remains to be established in clinical trials. Although the numbers are limited, nevertheless, this study provides a model for further research.

    View Abstract


    • Competing interests: none declared